Serological response to rabies virus induced by commercial vaccines in cattle

Mathias Martins¹ João Motta de Quadros² Eduardo Furtado Flores² Rudi Weiblen²

¹Programa de Pós-graduação em Medicina Veterinária, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brasil.
²Setor de Virologia, Departamento de Medicina Veterinária Preventiva, Centro de Ciências Rurais (CCR), Universidade Federal de Santa Maria (UFSM), 97105-900, Santa Maria, RS, Brasil. E-mail: eduardofurtadoflores@gmail.com. *Corresponding author.

ABSTRACT: The antibody response to rabies virus (RABV) induced by commercial vaccines in heifers was investigated. For this, 84 heifers were vaccinated twice (30 days interval) with each of four vaccines (G1 = 14 animals; G2 = 24; G3 = 22 and G4 = 24) and received a booster vaccination 360 days later. Serum samples collected at different intervals after vaccination and 30 days after booster were submitted to a virus neutralizing (VN) assay for RABV antibodies. Thirty days after the second vaccine dose, 92% of the immunized animals presented VN titers ≥0.5UI/mL (geometric medium titers [GMT] 1.7 to 3.8UI/mL). At the day of the booster (360 days post-vaccination); however, the percentage of animals harboring antibody titers ≥0.5UI/mL had dropped to 31% (0-80% of the animals, depending on the vaccine), resulting in lower GMT (0.1 to 0.6UI/mL). Booster vaccination at day 360 resulted in a detectable anamnestic response in all groups, resulting in 83% of animals (65 to 100%) harboring VN titers ≥0.5UI/mL thirty days later (GMT 0.6 to 4.3UI/mL). These results indicated that these vaccines were able to induce an adequate anti-RABV response in all animals after prime vaccination (and after booster as well). However, the titers decreased, reaching titers <0.5UI/mL in approximately 70% of animals within the interval before the recommended booster. Thus, booster vaccination for rabies in cattle using the current vaccines should be performed before the recommended one-year interval, as to maintain neutralizing antibodies levels in most vaccinated animals.

Key words: rabies, cattle, vaccines, neutralizing antibodies.

INTRODUCTION

Rabies is an acute and generally fatal neurological disease of mammals, including humans. Annually, an estimated number of 60,000 people die of rabies worldwide, mainly in African and Asian countries (OIE, 2016). The disease is caused by rabies virus (RABV), an enveloped RNA virus belonging to the family Rhabdoviridae, genus Lyssavirus (ICTV, 2015). RABV is maintained in nature in cycles involving wild and domestic animals, noticeably carnivores and bats (CONDORI-CONDORI et al., 2013). In South America,
the bat Desmodus rotundus is the main reservoir of RABV in nature, with frequent transmission to livestock, mainly cattle, horses and sheep (SCHNEIDER et al., 2009).

The economic losses associated with bovine rabies in Latin America may reach 15 million dollars, due to approximately 100 at 500 thousand deaths every year (HEINEMANN et al., 2002). Bovine rabies is endemic in most Brazilian regions represents an important sanitary and economic problem (HEINEMANN et al., 2002). Although, rabies is considered endemic in Brazil, the index varies between different regions of the country. Estimates of deaths reach up to 30.000 to 40.000 cattle annually (RODRIGUES DA SILVA et al., 2000; HEINEMANN et al., 2002).

Rabies vaccination is widely used in Brazilian regions where RABV infection is endemic, frequently associated with control of bat populations Desmodus rotundus (JOHNSON et al., 2014). Unfortunately, vaccination seems not to confer complete protection since bovine rabies has been reported even in vaccinated animals (LIMA et al., 2005). Indeed, some studies revealed a fast drop in neutralizing antibodies after vaccination, what could partially explain some vaccine failures (RIBEIRO NETTO et al., 1973; ALBAS et al., 1998; QUEIROZ DA SILVA et al., 2003). In addition, experimental data has demonstrated that booster vaccinations at somewhat short intervals are required for maintain adequate VN antibody titers (ITO et al., 1991; CÓRTES et al., 1993; RODRIGUES DA SILVA et al., 2000). Protection to RABV infection induced by vaccination is based mainly on neutralizing antibodies directed to the envelope glycoprotein G (WIKTOR et al., 1973; WUNDERLI et al., 1991). According to OIE, immunized animals must have levels of neutralizing antibodies of ≥0.5IU/mL.

Several inactivated, adjuvanted vaccines are available commercially and are widely used in Brazilian regions endemic for rabies. Licensed vaccines are subjected to an official quality control (MAPA, 2009). In spite of the manufacturer’s instructions (two 30-days apart initial doses followed by annual boosters), some producers perform only a single prime vaccination followed by occasional boosters, usually when cases of rabies are reported nearby (LIMA et al., 2005). The absence or incomplete vaccination protocols performed in most herds certainly contributes for the reported cases of rabies in vaccinated animals (FILHO et al., 2010; JOHNSON et al., 2014).

In Rio Grande do Sul (RS), the southernmost Brazil State, bovine rabies was historically endemic in well defined, restricted regions (FLORES – verbal report). Hence, vaccination was usually restricted to the affected and nearby herds. Beginning in 2011, an unprecedented rabies outbreak is occurring in the state, with estimates reaching up to 40.000 deaths by 2013 (SEAPA, 2013). In addition to the dramatic increase in the number of cases, the distribution of the disease also changed, with cases/outrbreaks occurring in otherwise free areas. As a consequence of the increase in the number of cases and expansion of the affected areas, rabies vaccination has been gradually implemented in many RS regions (FLORES – verbal report). Thus, the objective of this study was to evaluate the serological response of cattle to four commercial rabies vaccines, used according to the manufacturer’s recommendations.

**MATERIALS AND METHODS**

Eighty-four heifers (12 to 24 months-old) belonging to herds with no historic of vaccination against rabies in the central region of RS were used. Heifers were randomly allocated in four groups, each group receiving one commercial rabies vaccine, as follows: G1 = 14 animals; G2 = 24; G3 = 22 and G4 = 24. The four vaccines have been purchased in veterinary stores, kept refrigerated and used before the expiration date. All vaccines contain the RABV strain Pasteur virus (PV) inactivated and aluminum hydroxide as adjuvant. Animals were vaccinated according to the manufacturer’s instructions, receiving two doses subcutaneously (2mL) with a 30 day-interval, followed by a booster approximately 360 days later. Serum samples were collected at days 0 (first vaccine dose), 30 (second dose), 60, 360 (day of the booster) and 390 (30 days after booster). Serum samples were submitted to a modified RIFFT (rapid inhibition fluorescent focus test) for neutralizing antibodies to RABV, according to SMITH et al. (1973), with minor modifications. Briefly, 10-fold dilutions of serum were incubated with approximately 100-200 TCID$_{50}$ (50% tissue culture infective dose) of CVS (Challenge Virus Standard - CVS132-11A), kindly provided by Instituto Pasteur, São Paulo, Brazil) for 90min, followed by addition of a suspension of Baby Hamster Kidney cells (BHK-21 - C-13 ATCC CCL-107®) and incubation at 37°C - 5% of CO$_2$ for 48h. At the end of this period, the indicator cells were submitted to a fluorescent antibody (FA) assay, using an anti-RABV FITC-conjugate (Instituto Pasteur, São Paulo, Brazil). Mock-infected BHK-21 cells and cells infected with CVS were used as controls. Slides were observed in an UV epifluorescence microscope (AxioImmer ZEISS®). The virus neutralizing (VN) titer was considered the highest dilution of serum able to prevent virus replication, as indicated by the absence of viral antigens in indicator cells. A reference serum (containing 0.5UI/mL, provided by Instituto Pasteur, Sao Paulo, Brazil) was used as control in all tests. The neutralizing
Serological response to rabies virus induced by commercial vaccines in cattle.

Our results corroborated these findings, demonstrating that a single dose of the current inactivated vaccines is insufficient to induce suitable antibody levels. However, it should be emphasized that seroconversion at day 30pv (post-vaccination) should not be considered a definitive indicator of vaccine immunogenicity since the vaccine protocols recommend two initial doses 30 days apart. Unfortunately, many Brazilian farmers do not perform the complete vaccination protocol, applying only a single dose. According to our study and previous results, this simplified protocol results in low antibody titers and/or in a low percentage of seropositive cattle, leaving unprotected a considerable part of the herd (ALBAS et al., 2005).

At day 60 (30 days after the second vaccine dose), the heifers had seroconverted to RABV in titers ≥0.5UI/mL in percentages of 100% (G1), 95% (G2 and G3) and 76% (G4), respectively. The GMT ranged from 1.0 (G4) to 3.8UI/mL (G1). Again, G1 heifers developed the highest VN titers comparing to the other groups (P<0.05). Thus, considering the recommended protocol of two initial doses, three out of four vaccines were able to induce VN titers above the cut-off value recommended by OIE (≥0.5UI/mL) against RABV in at least 95% of heifers. Surprisingly, only 76% of the animals of one vaccine group (G4) developed antibody titers higher than 0.5UI/mL after the second dose. The reasons for this low performance are unclear and somewhat surprising since these vaccines are expected to fulfill the official requirements that include innocuity, sterility and potency before are made available for commercial use (MAPA, 2009).

In general, the VN titers at day 60 were well above the reference value, in at least three vaccine groups (in some cases they reached up to 8UI/mL). The magnitude of VN titers, as indicated by GMT, was highly variable among the groups, indicating important differences in the immunogenicity among the vaccines.

### RESULTS AND DISCUSSION

The results of RIFFT assays for RABV neutralizing antibodies in the sera of heifers immunized with commercial vaccines are presented in table 1 and figure 1. Table 1 presents the number and percentage of seropositive cattle (titers ≥0.5UI/mL) and the GMT of the vaccinated animals after vaccination and booster; figure 1 shows the evolution of VN titers (expressed as GMT) at these time points.

None of the vaccinated animals had VN antibodies to RABV at the day of first vaccination, as verified by the RIFFT (not shown). Thirty days after the first vaccine dose, 57% of the animals presented VN titers ≥0.5UI/mL (Table 1). The percentage of seropositive cattle varied among the groups, from 25% (G2) to 86% (G1). The GMT at this day ranged from 0.3 (G2) to 1.4UI/mL (G1). In naïve animals, a single dose of inactivated rabies vaccine has been considered insufficient for adequate immunization (ALBAS et al., 1998; FILHO et al., 2010). ALBAS et al. (2005) compared different vaccination protocols with a commercial vaccine containing inactivated RABV (strain PV) and aluminum hydroxide as adjuvant. When evaluating the neutralizing antibody titers 30 days after the first vaccination, only 30% of the animals had developed neutralizing antibodies in titers ≥0.5UI/mL. Our results corroborated these findings, demonstrating that a single dose of the current inactivated vaccines is insufficient to induce suitable antibody levels.

### Table 1 – Serological response of heifers to rabies virus following vaccination and booster with each of four commercial rabies vaccines.

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>% seropositive cattle</th>
<th>GMT</th>
<th>% seropositive cattle</th>
<th>GMT</th>
<th>n</th>
<th>% seropositive cattle</th>
<th>GMT</th>
<th>% seropositive cattle</th>
<th>GMT</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>14</td>
<td>86 (12/14)</td>
<td>1.4</td>
<td>100 (14/14)</td>
<td>3.8</td>
<td>10</td>
<td>80 (8/10)</td>
<td>0.6</td>
<td>100 (10/10)</td>
<td>4.3</td>
</tr>
<tr>
<td>G2</td>
<td>24</td>
<td>25 (6/24)</td>
<td>0.3</td>
<td>95 (23/24)</td>
<td>1.9</td>
<td>17</td>
<td>23 (4/17)</td>
<td>0.2</td>
<td>65 (11/17)</td>
<td>0.8</td>
</tr>
<tr>
<td>G3</td>
<td>22</td>
<td>73 (16/22)</td>
<td>0.5</td>
<td>95 (21/22)</td>
<td>1.7</td>
<td>15</td>
<td>27 (4/15)</td>
<td>0.1</td>
<td>87 (13/15)</td>
<td>0.6</td>
</tr>
<tr>
<td>G4</td>
<td>24</td>
<td>58 (14/24)</td>
<td>0.5</td>
<td>76 (19/24)</td>
<td>1.0</td>
<td>10</td>
<td>0 (0/10)</td>
<td>0.1</td>
<td>90 (9/10)</td>
<td>1.0</td>
</tr>
<tr>
<td>Total</td>
<td>84</td>
<td>57 (48/84)</td>
<td>0.8</td>
<td>92 (77/84)</td>
<td>1.0</td>
<td>52</td>
<td>31 (16/52)</td>
<td>0.8</td>
<td>83 (43/52)</td>
<td>1.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Post-vaccination;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determined by a VN assay. Seropositive cattle were the animals with VN titers of ≥0.5UI/mL;</td>
</tr>
<tr>
<td>Geometric mean titer;</td>
</tr>
<tr>
<td>Between vaccination and the booster, number of animals decreased from 84 to 52 for reasons unrelated to the experiment.</td>
</tr>
</tbody>
</table>

PIZA et al. (2002) verified that the quantification of virus attached rabies glycoprotein present in vaccines, has a strong correlation with VNA elicited in the target species. This could explain the observed differences between the vaccines we tested. However, we did not assess the virus attached rabies glycoprotein, nor total glycoprotein nor free soluble glycoprotein. Thus, it is not possible to attribute the observed differences to this factor. As mentioned before, licensed rabies vaccines are subjected to official control by the Brazilian Ministry of Agriculture Livestock and Supply (MAPA).

Our results confirmed the adequate immunogenicity of at least three of these vaccines, as ascertained by VN titers developed in >95% animals at day 60pv.

At the day of the booster, the percentage of animals with titers ≥0.5UI/mL had dropped dramatically comparing to day 60. Percentage of animals with titers ≥0.5UI/mL ranged from 0 (G4) to 80% (G1). These results indicated that approximately 31% (20 to 100%, depending on the vaccine) of the vaccinated animals would become unprotected to rabies (antibody VN titers lower then ≥0.5UI/mL) before the time recommended for booster. At this day, the GMT were also significantly lower (0.1 to 0.6UI/mL), illustrating the VN very low antibody levels after the one year-interval. The fast decline in VN titers induced by inactivated RABV vaccines has also been observed in other studies. ALBAS et al. (2005) evaluated the neutralizing antibody titers 360 after vaccination and observed that none of the nine vaccinated animals was able to maintain adequate antibody titers. In other study, ALBAS et al. (1998) investigated the importance of the booster in the duration of immune response, observing that only 19% of the animals receiving two vaccine doses, 30 days apart, were able to maintain antibody titers >0.5UI/mL at day 360. Our results corroborated these findings, indicating an early decrease of neutralizing antibody titers in most vaccinated animals.

Following the manufacturer’s recommendations, we performed a booster vaccination approximately 360 days after the initial vaccination. Sera of vaccinated animals were tested for RABV neutralizing antibodies at the day of the booster and 30 days later. Analyzing the individual vaccines, only G1 was able to maintain adequate antibody levels in a high proportion of animals (80%) during the one-year interval. Considering that the vaccination protocols recommend a booster vaccination one year after the prime vaccination, a high percentage of animals (69%) would be unprotected before receiving the booster. This window of

Figure 1 - Evolution of the geometric mean titers (GMT) of virus-neutralizing antibodies in the sera of heifers vaccinated with each of four commercial rabies vaccines. G1-G4: vaccine groups. * and ** are different (P<0.05).
The most important finding was that adequate VN variation in the immunogenicity among the vaccines. Differences in GMT; however, indicated an important response in all vaccine groups. The significant protocol. Booster immunization revealed an anamnestic animals after completion of the prime vaccination e.g. conferring adequate VN levels in the vaccinated following boosters.

Interestingly, vaccine G4 had the worst performance at higher titers were indeed reached soon after booster. (3.8UI/mL). The other vaccines provided a boost antibody titers may be observed earlier (RODRIGUES sera was collected 30 days post-booster and the peak of lower than those measured at day 60pv (Figure 1). As the groups G2, G3 and G4 post-booster were significantly were not maintained over the period of one year in 69% of the animals, indicating the need of shortening the interval between vaccination and booster, mainly in regions of high infection pressure.

INFORMAL INFORMATION

The authors thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for the scholarships, Matheus M. received doctoral scholarship (process 142148/2011-3), João M.Q. received scientific initiation scholarship (process 135068/2016-9) and Eduardo F.F. (process 301414/2010-6) and Rudi W. (process 304153/2014-1) were supported by research productivity fellowship.

REFERENCES


Erratum

In the article "Serological response to rabies virus induced by commercial vaccines in cattle" published in Ciência Rural, volume 47, number 10, DOI http://dx.doi.org/10.1590/0103-8478cr20161044.

In several moments in the article, where it reads:

UI/mL

Read it:

UI mL⁻¹

In the Abstract, where it reads:

At the day of the booster (360 days post-vaccination); however

Read it:

However, at the day of the booster (360 days post-vaccination)

In the Resumo, where it reads:

GMT

Read it:

TMG (título médio geométrico)

In the Materials and Methods, where it reads:

Sao Paulo

Read it:

São Paulo

In the table 1, where it reads:

pv

Read it:

dpv
Where it reads:
Post-vaccination

Read it:
Days post-vaccination

In the Results and Discussion, where it reads:
antibody VN titers lower then $\geq 0.5\text{UI/mL}$

Read it:
antibody VN titers lower then $0.5\text{UI mL}^{-1}$

Where it reads:
$(0.6$ to $4.3 \geq 0.5\text{UI mL}^{-1})$

Read it:
$(0.6$ to $4.3\text{UI mL}^{-1})$